FMI - Just 3 months ago, Roche paid $50/share to take approx. 80% of the company and FMI now sits at $23/share is ridiculously cheap, FMI earning report doesn't look good based on the numbers of tests it performed; however, it makes the Roche deal looks very bad. Is it better for Roche to buy the remaining shares of FMI at a discount price?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.